Pharmacogenetics of juvenile idiopathic arthritis - A genome wide association study on the efficacy and toxicity of methotrexate therapy

幼年特发性关节炎的药物遗传学 - 关于甲氨蝶呤治疗的功效和毒性的全基因组关联研究

• 批准号: 209212
• 负责人: Schmeling Heinrike
• 金额: $ 20.4万
• 依托单位: University of Calgary
• 依托单位国家: 加拿大
• 项目类别: Salary Programs
• 财政年份: 2010
• 资助国家: 加拿大
• 起止时间: 2010-07-01 至 2012-07-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=209212&lang=en
• 关键词: Childhood Arthritis; Methotrexate; Pharmacogenetics

Methotrexate is the most commonly used immunosuppressive medication for children with chronic arthritis. This research focuses on identifying key gene variants that predict response to methotrexate and treatment-related toxicity. An international partners

甲氨蝶呤是儿童慢性关节炎最常用的免疫抑制药物。本研究的重点是确定预测甲氨蝶呤反应和治疗相关毒性的关键基因变异。国际合作伙伴